Royalty Pharma Resultados de beneficios anteriores

Pasado controles de criterios 3/6

Los beneficios de Royalty Pharma han disminuido a una tasa media anual de -36.6%, mientras que en la industria Pharmaceuticals los beneficios crecieron en un 0.1% anualmente. Los ingresos han ido creciendo a una tasa media de 0.5% al año. La rentabilidad financiera de Royalty Pharma es de 10.6%, y sus márgenes netos son de 30.1%.

Información clave

-36.6%

Tasa de crecimiento de los beneficios

-40.2%

Tasa de crecimiento del BPA

Crecimiento de la industria Pharmaceuticals	6.0%
Tasa de crecimiento de los ingresos	0.5%
Rentabilidad financiera	10.6%
Margen neto	30.1%
Última actualización de beneficios	30 Jun 2024

Actualizaciones de resultados anteriores recientes

Royalty Pharma's (NASDAQ:RPRX) Earnings Are Weaker Than They Seem

Feb 22

Recent updates

Royalty Pharma plc (NASDAQ:RPRX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 12

Royalty Pharma: Solid Start Of The Year, Buy Confirmed

May 11

Royalty Pharma (NASDAQ:RPRX) Will Pay A Dividend Of $0.21

Apr 28

Unpleasant Surprises Could Be In Store For Royalty Pharma plc's (NASDAQ:RPRX) Shares

Apr 25

Is Royalty Pharma (NASDAQ:RPRX) Using Too Much Debt?

Apr 04

Royalty Pharma's (NASDAQ:RPRX) Earnings Are Weaker Than They Seem

Feb 22

Royalty Pharma: Solid Operational Performance

Feb 19

Royalty Pharma (NASDAQ:RPRX) Will Pay A Larger Dividend Than Last Year At $0.21

Jan 31

Royalty Pharma: One Of The Best Names In Pharmaceuticals

Jan 22

Royalty Pharma plc's (NASDAQ:RPRX) Share Price Matching Investor Opinion

Dec 26

Royalty Pharma's (NASDAQ:RPRX) Upcoming Dividend Will Be Larger Than Last Year's

May 12

Royalty Pharma (NASDAQ:RPRX) Is Increasing Its Dividend To $0.20

Apr 20

Royalty Pharma's (NASDAQ:RPRX) Dividend Will Be Increased To $0.20

Jan 16

Royalty Pharma to co-fund development of schizophrenia drug with Merck

Oct 12

Royalty Pharma: Strategic Royalty Interest Acquisition To Drive Significant Growth

Aug 18

Desglose de ingresos y gastos

Cómo gana y gasta dinero Royalty Pharma. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

NasdaqGS:RPRX Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
30 Jun 24	2,238	673	229	52
31 Mar 24	2,239	799	222	52
31 Dec 23	2,355	1,135	250	52
30 Sep 23	2,324	184	264	102
30 Jun 23	2,361	255	257	77
31 Mar 23	2,359	332	261	77
31 Dec 22	2,237	43	227	177
30 Sep 22	2,247	507	200	230
30 Jun 22	2,259	466	198	295
31 Mar 22	2,278	602	191	298
31 Dec 21	2,289	620	183	200
30 Sep 21	2,286	783	187	104
30 Jun 21	2,239	972	189	19
31 Mar 21	2,195	493	187	21
31 Dec 20	2,122	495	182	26
30 Sep 20	2,008	1,745	155	34
30 Jun 20	1,934	1,863	130	52
31 Mar 20	1,880	2,052	117	68
31 Dec 19	1,814	2,349	103	83
31 Dec 18	1,795	1,378	62	393
31 Dec 17	1,598	1,210	106	118

Ingresos de calidad: RPRX tiene una única gran ganancia de $249.2M que afecta a sus resultados financieros de los últimos 12 meses de 30th June, 2024.

Margen de beneficios creciente: Los actuales márgenes de beneficio (30.1%) de RPRX son superiores a los del año pasado (10.8%).

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: Los beneficios de RPRX han disminuido en un 36.6% al año en los últimos 5 años.

Acelerando crecimiento: El crecimiento de los beneficios de RPRX en el último año (164.1%) supera su media de 5 años (-36.6% al año).

Beneficios vs. Industria: El crecimiento de los beneficios de RPRX en el último año (164.1%) superó al de la industria Pharmaceuticals 36.7%.

Royalty Pharma Resultados de beneficios anteriores

Pasado controles de criterios 3/6

Información clave

Actualizaciones de resultados anteriores recientes

Royalty Pharma plc to Report Q3, 2024 Results on Nov 06, 2024

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Royalty Pharma plc to Report Q2, 2024 Results on Aug 08, 2024

First quarter 2024 earnings released: EPS: US$0.011 (vs US$0.77 in 1Q 2023)

Royalty Pharma plc to Report Q1, 2024 Results on May 09, 2024

Royalty Pharma's (NASDAQ:RPRX) Earnings Are Weaker Than They Seem

Recent updates

Price target decreased by 7.7% to US$41.43

Royalty Pharma plc to Report Q3, 2024 Results on Nov 06, 2024

Royalty Pharma (NASDAQ:RPRX) Has Affirmed Its Dividend Of $0.21

Second quarter dividend of US$0.21 announced

Royalty Pharma Declares Fourth Quarter 2024 Dividend, Payable on December 10, 2024

Earnings Tell The Story For Royalty Pharma plc (NASDAQ:RPRX)

Royalty Pharma (NASDAQ:RPRX) Takes On Some Risk With Its Use Of Debt

Royalty Pharma plc Q2: Beat And Raise Reaffirm Our Buy Rating

Consensus EPS estimates fall by 33%

Royalty Pharma: Busy Putting Capital To Work

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Upcoming dividend of US$0.21 per share

Royalty Pharma plc Appoints Molly Sawaya as Executive Vice President, Head of Human Capital

Royalty Pharma (NASDAQ:RPRX) Has Announced A Dividend Of $0.21

First quarter dividend of US$0.21 announced

Royalty Pharma plc to Report Q2, 2024 Results on Aug 08, 2024

Royalty Pharma plc Declares Dividend for the Third Quarter of 2024, Payable on September 13, 2024

Royalty Pharma plc Announces the Resignation of Rory Balfour Riggs as Director

Royalty Pharma plc Announces Resignation of Mario Germano Giuliani as Director

Consensus EPS estimates fall by 10%

Royalty Pharma plc (NASDAQ:RPRX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Royalty Pharma: Solid Start Of The Year, Buy Confirmed

First quarter 2024 earnings released: EPS: US$0.011 (vs US$0.77 in 1Q 2023)

Upcoming dividend of US$0.21 per share

Royalty Pharma (NASDAQ:RPRX) Will Pay A Dividend Of $0.21

Royalty Pharma plc, Annual General Meeting, Jun 06, 2024

Unpleasant Surprises Could Be In Store For Royalty Pharma plc's (NASDAQ:RPRX) Shares

Fourth quarter dividend of US$0.21 announced

Royalty Pharma plc Declares Dividend for the Second Quarter of 2024, Payable on June 14, 2024

Royalty Pharma plc to Report Q1, 2024 Results on May 09, 2024

Is Royalty Pharma (NASDAQ:RPRX) Using Too Much Debt?

Royalty Pharma's (NASDAQ:RPRX) Earnings Are Weaker Than They Seem

Consensus EPS estimates increase by 79%

Royalty Pharma: Solid Operational Performance

Full year 2023 earnings released: EPS: US$2.54 (vs US$0.098 in FY 2022)

Upcoming dividend of US$0.21 per share at 2.9% yield

Royalty Pharma (NASDAQ:RPRX) Will Pay A Larger Dividend Than Last Year At $0.21

Royalty Pharma plc to Report Q4, 2023 Results on Feb 15, 2024

Royalty Pharma: One Of The Best Names In Pharmaceuticals

Royalty Pharma plc Declares Dividend for the First Quarter of 2024, Payable on March 15, 2024

Consensus EPS estimates increase by 68%

Director notifies of intention to sell stock

Director recently sold US$7.1m worth of stock

Royalty Pharma plc's (NASDAQ:RPRX) Share Price Matching Investor Opinion

Director recently sold US$19m worth of stock

Director notifies of intention to sell stock

Consensus EPS estimates increase by 94%

Third quarter 2023 earnings released: EPS: US$0.16 (vs US$0.33 in 3Q 2022)

Upcoming dividend of US$0.20 per share at 2.9% yield

Consensus EPS estimates increase by 55%

Consensus EPS estimates increase by 15%

Royalty Pharma Appoints Eric Schneider as Chief Technology Officer

Executive VP & CFO recently sold US$2.3m worth of stock

Executive VP & CFO notifies of intention to sell stock

Upcoming dividend of US$0.20 per share at 2.6% yield

Second quarter 2023 earnings released: EPS: US$0.51 (vs US$0.70 in 2Q 2022)

Insufficient new directors

Royalty Pharma plc Declares Dividend on Class A Ordinary Shares for the Third Quarter of 2023, Payable on September 15, 2023

Executive VP & CFO recently sold US$2.3m worth of stock

Executive VP & CFO notifies of intention to sell stock

Founder recently bought US$3.8m worth of stock

Royalty Pharma plc to Report Q2, 2023 Results on Aug 08, 2023

Insider recently sold US$6.5m worth of stock

Insider notifies of intention to sell stock

Director notifies of intention to sell stock

Founder recently bought US$7.7m worth of stock

Consensus EPS estimates increase by 243%

Royalty Pharma's (NASDAQ:RPRX) Upcoming Dividend Will Be Larger Than Last Year's

Upcoming dividend of US$0.20 per share at 2.4% yield